NF-κB信号通路在恶性肿瘤化疗耐药中的作用

doi:10.11904/j.issn.1002-3070.2021.06.019

摘要/Abstract

摘要： 恶性肿瘤已然成为影响人们健康的最主要原因,化疗是应用最广泛最有效的抗肿瘤治疗手段之一。然而,随着化疗药物的使用,肿瘤细胞会产生耐药性,成为影响化疗效果的主要原因。耐药的产生可能涉及众多机制,包括细胞周期调控异常、凋亡信号通路受阻、耐药基因的异常表达等。近年来的研究表明,细胞存活信号通路在肿瘤化疗耐药中有着重要作用。核转录因子κB(Nuclear factor kappa B,NF-κB)信号通路的异常是恶性肿瘤耐药的主要机制之一。因此,NF-κB信号通路也可能成为克服恶性肿瘤耐药的有效靶点。本综述简要归纳NF-κB信号通路在恶性肿瘤化疗耐药中的作用和研究进展。

关键词: NF-κB, 信号通路, 恶性肿瘤, 化疗耐药

Abstract: Malignant tumors have become the main reason affecting people′s health.Chemotherapy is one of the most widely used and most effective anti-tumor treatments.However,with the use of chemotherapeutic drugs,tumor cells will develop drug resistance,which becomes the main reason that affects the effect of chemotherapy.The emergence of drug resistance may involve many mechanisms,including abnormal cell cycle regulation,blockage of apoptotic signaling pathways,and abnormal expression of drug resistance genes.Recent studies have shown that cell survival signaling pathways play an important role in tumor chemotherapy resistance.The abnormality of nuclear factor kappa B(NF-κB)signaling pathway is one of the main mechanisms of drug resistance in malignant tumors.Therefore,NF-κB signaling pathway may also become an effective target for overcoming drug resistance in malignant tumors.This review briefly summarizes the role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors and its research progress.

Key words: NF-κB, Signaling pathway, Cancer, Chemotherapy resistance

中图分类号:

李娜, 邓茜, 蒋建军. NF-κB信号通路在恶性肿瘤化疗耐药中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 580-584.

LI Na, DENG Qian, JIANG Jianjun. The role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors[J]. Journal of Practical Oncology, 2021, 35(6): 580-584.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/580

参考文献

1 Goldstein LJ,Galski H,Fojo A,et al.Expression of a multidrug resistance gene in human cancers[J].J Natl Cancer Inst,1989,81(2):116-124.
2 Cho H,Thorvaldsen JL,Chu Q,et al.Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice[J].Biol Chem,2001,276(42):38349-38352.
3 Kim CK,Nguyen TL,Lee SB,et al.Akt2 and nucleophosmin/B23 function as an oncogenic unit in human lung cancer cells[J].Exp Cell Res,2011,317(7):966-975.
4 Arsura M,Cavin LG.Nuclear factor-kappaB and liver carcinogenesis[J].Cancer Lett,2005,229(2):157-169.
5 Baumgartner B,Weber M,Quirling M,et al.Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts[J].Leukemia,2002,16(10):2062-2071.
6 Xue YS,Yang L,Li JZ,et al.Combination chemotherapy with Zyflamend reduced the required resistance of bladder cancer cels to cisplatin through inhibiting NF-κB signaling pathway[J].Onco Targets Ther,2018,11:4413-4429.
7 Hafsi S,Pezzino F,Candido S,et al.Gene alterations in the Pl3K/PTEN/AKT pathway as a mechanism of drug-resistance(review)[J].Int J Oncol,2012,40(3):639-644.
8 Riquelme I,Tapia O,Espinoza JA,et al.The gene expression status of the Pl3K/AKT/mTOR pathway in gastric cancer tissues and cell lines[J].Pathol Oncol Res,2016,22(4):797-805.
9 Bacheru U,Kern W,Hafe R,et al.Cyclin D1(CCND1)messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma[J].Exp Hematol,2013,41(12):1028-1037.
10 黄虎,栗娜,杨柳,等.非小细胞肺癌组织中NF-κB和CyclinD1及p27表达与患者化疗敏感性[J].贵州医科大学学报,2019,44(2):195-199.
11 Sheng YH,Choa P,Lourie R,et al.MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance[J].Int J Cancer,2017,140(10):2351-2363.
12 Bidwell GL,Raucher D.Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc[J].Biochem Pharmacol,2006,71(3):248-256.
13 Mohammad S,Ava SA,Atieh PS,et al.c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB[J].Arch Med Res,2020,51(7):636-644.
14 Sun D,Wang X,Sui GQ,et al.Downregulation of mi R-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins[J].Int J Oncol,2018,52(5):1491-1503.
15 Raˇckauskas R,Zhou DC,selis S,et al.Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins[J].Oncol Rep,2017,37(6):3660-3666.
16 Semba S,Trapasso F,Fabbri M,et al.Fhit modulation of the Akt-survivin pathway in lung cancer cells:Fhit-tyrosine 114(Y114)is essential[J].Oncogene,2006,25(20):2860-2872.
17 Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
18 Piovani G,Savio G,Traversa M,et al.De novo 1Mb interstitial deletion of 8p22 in a patient with slight mental retardation and speech delay[J].Mol Cytogenet,2014,7:25.
19 武潮.MicroRNA-383调控非小细胞肺癌细胞对顺铂敏感性的作用及机制研究[D].重庆:西南大学,2020.
20 Huang RS,Zheng YL,Zhao J,et al.microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling[J].Biomed Pharmacother,2018,98:538-544.
21 Wang ZY,Wang N,Liu PX,et al.MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells,a process modulated by the natural autophagy inducer isoliquiritigenin[J].Oncotarget,2014,5(16):7013-7026.
22 Yang HL,Zheng YC,Zhang YZ,et al.Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling[J].Leuk Res,2017,60:82-88.
23 Zhang LH,Yang AJ,Wang M,et al.Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells[J].Apoptosis,2016,21(4):473-488.
24 Zhou Y,Uddin S,Zimmerman T,et al.Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3[J].Leuk Lymphoma,2008,49(10):1945-1953.
25 Kroemer G,Pouyssegur J.Tumor cell metabolism:cancer′s Achilles′ heel[J].Cancer Cell,2008,13(6):472-482.
26 Fritz V,Fajas L.Metabolism and proliferation share common regulatory pathways in cancer cells[J].Oncogene,2010,29(31):4369-4377.
27 Liu T,Wei RD,Zhang YT,et al.Association between NF-κB expression and drug resistance of liver cancer[J].Oncol Lett,2019,17(1):1030-1034.
28 Chen Q,Liu X,Luo Z,et al.Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression[J].J Cell Physiol,2019,234(5):6611-6623.
29 赵宝霞,刘思琪,董思聪,等.Bmi-1 介导的 K562/ADR 细胞多药耐药机制[J].中国实验血液学杂志,2020,28(3):758-766.
30 王子元,孙明瑜,陈佳,等.健脾解毒方通过NF-κB/Nrf2/MRP2信号通路逆转大肠癌多药耐药的作用机制[J].中华中医药杂志,2020,35(7):3367-3371.
31 Lin X,Zhang X,Wang Q,et al.Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line[J].Neoplasma,2012,59(3):248-256.
32 Muthusamy G,Gunaseelan S,Prasad NR.Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway[J].J Nutr Biochem,2019,63:62-71.
33 赵宝霞,刘思琪,董思聪,等.Bmi-1 介导的 K562/ADR 细胞多药耐药机制[J].中国实验血液学杂志,2020,28(3):758-766.
34 杜国良,赵宗茂,宋建抢,等.核转录因子-κB抑制剂逆转胶质瘤细胞株对替莫唑胺的耐药性[J].中华实验外科杂志,2018,35(8):1476-1478.
35 Qiu YX,Dai Y,Zhang C.et al.Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma:a targeted intervention of 14-3-3η/NF-κB feedback loop[J].J Exp Clin Cancer Res,2018,37(1):321.
36 刘俊峰,谢涛,刘羽,等.核因子-κB抑制剂对胶质瘤干细胞放疗增敏的作用[J].中华实验外科杂志,2018,35(9):1684-1686.

[1]	符艳, 颜李丽, 王春雨, 符芳敏, 董华. 2010—2016年琼海市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(5): 396-401.
[2]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[3]	范琳, 田霖丽, 刘鸣. 单细胞测序技术在头颈部恶性肿瘤中的研究与发展[J]. 实用肿瘤学杂志, 2021, 35(5): 472-475.
[4]	董华, 王定彬, 华婧, 范康琼, 马楠楠, 王兴任. 2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2021, 35(4): 344-350.
[5]	陈莉莉, 刘玉琴, 丁高恒, 苏海翔. 甘肃省恶性肿瘤流行情况及防控现状[J]. 实用肿瘤学杂志, 2021, 35(3): 254-257.
[6]	国昊楠, 秦韬. MYO10与恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 273-276.
[7]	潘红艳, 李爱萍, 李强. 脂肪因子Omentin-1与肿瘤相关性的研究[J]. 实用肿瘤学杂志, 2021, 35(3): 282-286.
[8]	尹琦, 胡彦建, 崔普泽, 胡彦华. Notch信号通路调控肿瘤细胞凋亡机制研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 165-169.
[9]	郑志远,综述,曲国蕃(审校). 长链非编码RNA SNHG3在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 50-54.
[10]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[11]	文洪梅, 陈杨, 石青萍, 任思颖, 高娇, 秦明芳. 2016年云南省肿瘤登记地区恶性肿瘤的发病和死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 485-490.
[12]	相智声, 马晶昱, 钟文玲, 陈铁晖, 林永添, 江惠娟, 周衍. 福建省2016年恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 491-494.
[13]	李建昕, 沈彬杰, 王璇. 恶性肿瘤社区随访模式的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 540-543.
[14]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[15]	韩仁强, 武鸣, 缪伟刚, 罗鹏飞, 俞浩, 周金意. 2016年江苏省恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 291-297.